Literature DB >> 12491165

Conditional virus replication as an approach to a safe live attenuated human immunodeficiency virus vaccine.

Ben Berkhout1, Koen Verhoef, Giuseppe Marzio, Bep Klaver, Monique Vink, Xue Zhou, Atze T Das.   

Abstract

Despite intensive efforts, no safe and effective vaccine has been developed for the prophylaxis of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS). Studies with the simian immunodeficiency virus (SIV)/macaque model demonstrated that live attenuated viruses are the most effective vaccines tested thus far. However, due to ongoing low-level replication of the attenuated virus and the error-prone replication machinery, the attenuated virus may regain replication capacity and become pathogenic. We therefore designed a novel vaccine strategy with an HIV-1 virus that replicates exclusively in the presence of the nontoxic effector doxycycline (dox). This was achieved by replacement of the viral TAR-Tat system for transcriptional activation by the Escherichia coli-derived Tet system for inducible gene expression. This designer HIV-rtTA virus replicates in a strictly dox-dependent manner and may represent an improved vaccine strain because its replication can be turned on and off at will. Spontaneous virus evolution resulted in optimization of the components of the Tet system for their new function to support virus replication in human cells. The optimised Tet system may be of particular use in other applications such as inducible expression of gene therapy vectors in the brain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12491165     DOI: 10.1080/13550280290101102

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  3 in total

1.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine.

Authors:  Mauro Pistello; Donatella Matteucci; Francesca Bonci; Patrizia Isola; Paola Mazzetti; Lucia Zaccaro; Antonio Merico; Daniela Del Mauro; Norman Flynn; Mauro Bendinelli
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

2.  Construction of doxycyline-dependent mini-HIV-1 variants for the development of a virotherapy against leukemias.

Authors:  Rienk E Jeeninga; Barbara Jan; Henk van den Berg; Ben Berkhout
Journal:  Retrovirology       Date:  2006-09-27       Impact factor: 4.602

3.  Transient CRISPR-Cas Treatment Can Prevent Reactivation of HIV-1 Replication in a Latently Infected T-Cell Line.

Authors:  Ye Liu; Rienk E Jeeninga; Bep Klaver; Ben Berkhout; Atze T Das
Journal:  Viruses       Date:  2021-12-08       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.